Inviting an author to review:
Find an author and click ‘Invite to review selected article’ near their name.
Search for authorsSearch for similar articles
39
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Antiretroviral treatment interruption among people living with HIV during COVID‐19 outbreak in China: a nationwide cross‐sectional study

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction

          Social disruption associated with coronavirus disease 2019 (COVID‐19) threatens to impede access to regular healthcare, including for people living with HIV (PLHIV), potentially resulting in antiretroviral therapy (ART) interruption (ATI). We aimed to explore the characteristics and factors associated with ATI during the COVID‐19 outbreak in China.

          Methods

          We conducted an online survey among PLHIV by convenience sampling through social media between 5‐17 February 2020. Respondents were asked to report whether they were at risk of ATI (i.e., experienced ATI, risk of imminent ATI, threatened but resolved risk of ATI [obtaining ART prior to interruption]) or were not at risk of ATI associated with the COVID‐19 outbreak. PLHIV were also asked to report perceived risk factors for ATI and sources of additional ART. Factors associated with risk of ATI were assessed using logistic regression. We also evaluated factors associated with experienced ATI.

          Results

          A total of 5084 PLHIV from 31 provinces, autonomous regions and municipalities in mainland China completed the survey, with a response rate of 99.4%. Median age was 31 years (IQR 27‐37), 96.5% of participants were men, and 71.3% were men who had sex with men. Over one‐third (35.1%, 1782/5084) reported any risk of ATI during the COVID‐19 outbreak, including 2.7% (135/5084) who experienced ATI, 18.0% (917/5084) at risk of imminent ATI, and 14.4% (730/5084) at threatened but resolved risk. PLHIV with ATI were more likely to have previous interruptions in ART (aOR 8.3, 95% CI 5.6‐12.3), traveled away from where they typically receive HIV care (aOR 3.0, 95% CI 2.1‐4.5), stayed in an area that implemented citywide lockdowns or travel restrictions to control COVID‐19 (aOR 2.5, 95% CI 1.4‐4.6), and be in permanent residence in a rural area (aOR 3.7, 95% CI 2.3‐5.8).

          Conclusions

          A significant proportion of PLHIV in China are at risk of ATI during the COVID‐19 outbreak and some have already experienced ATI. Correlates of ATI and self‐reported barriers to ART suggest that social disruptions from COVID‐19 have contributed to ATI. Our findings demonstrate an urgent need for policies and interventions to maintain access to HIV care during public health emergencies.

          Related collections

          Author and article information

          Contributors
          caiyong202028@hotmail.com
          zouhuachun@mail.sysu.edu.cn
          Journal
          J Int AIDS Soc
          J Int AIDS Soc
          10.1002/(ISSN)1758-2652
          JIA2
          Journal of the International AIDS Society
          John Wiley and Sons Inc. (Hoboken )
          1758-2652
          28 October 2020
          : e25637
          Affiliations
          [ 1 ] School of Public Health (Shenzhen) Sun Yat‐sen University Shenzhen China
          [ 2 ] Shizhong District Center for Disease Control and Prevention Jinan China
          [ 3 ] Wuxi Municipal Center for Disease Control and Prevention Wuxi China
          [ 4 ] UNAIDS China Office Beijing China
          [ 5 ] Department of Internal Medicine University of Washington Seattle Washington USA
          [ 6 ] Department of Infectious Diseases Guangzhou Eighth People’s Hospital affiliated to Guangzhou Medical School Guangzhou China
          [ 7 ] Chongqing Blue Sky nongovernment organization Chongqing China
          [ 8 ] School of Public Health Shanghai Jiao Tong University School of Medicine Shanghai China
          [ 9 ] SJTU‐Yale Joint Center for Biostatistics and Data Science Department of Bioinformatics and Biostatistics School of Life Science and Biotechnology Shanghai Jiao Tong University (SJTU) Shanghai China
          [ 10 ] Yale School of Public Health New Haven Connecticut USA
          [ 11 ] Shenzhen Center for Disease Control and Prevention Shenzhen China
          [ 12 ] Kirby Institute University of New South Wales Sydney Australia
          Author notes
          [*] [* ] Corresponding authors

          Prof. Huachun Zou, Postal address: 74 Zhongshan 2nd Road, Yuexiu District, Guangzhou, Guangdong, 510085, China, Telephone number: +86 20 87335651

          Email: zouhuachun@ 123456mail.sysu.edu.cn

          Prof. Yong Cai, Postal address: No.227 South Chongqing Road, Shanghai, 200025, China, Telephone number: +86 21 63846590

          Email: caiyong202028@ 123456hotmail.com

          [†]

          These authors have contributed equally to the work.

          Author information
          https://orcid.org/0000-0001-9946-9877
          https://orcid.org/0000-0003-3126-1134
          https://orcid.org/0000-0002-5706-7906
          https://orcid.org/0000-0002-8161-7576
          Article
          JIA225637
          10.1002/jia2.25637
          7645858
          33247541
          eb42e75e-04da-46d9-bbdc-ffa7ab4d1f1a
          This article is protected by copyright. All rights reserved.

          This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

          History
          Page count
          Figures: 0, Tables: 0, Pages: 37, Words: 627
          Categories
          Research Article
          Research Articles
          Custom metadata
          2.0
          accepted-manuscript
          Converter:WILEY_ML3GV2_TO_JATSPMC version:5.9.3 mode:remove_FC converted:06.11.2020

          Infectious disease & Microbiology
          antiretroviral therapy interruption,antiretroviral therapy,hiv,lockdown,covid‐19,china

          Comments

          Comment on this article